Mirati Therapeutics

Youtube Subscribe

Open: 36.57 Close: 35.19 Change: -1.38

Our AI found some flaws in Mirati Therapeutics.

This document will help you to evaluate Mirati Therapeutics without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Mirati Therapeutics are: Mirati, interim, Therapeutics, CFO, stock, Aaron, Ondrey, …

Concept Map

Semantic Network

Stock Summary

Mirati Therapeutics, Inc. provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC).

Today's Summary

Aaron Ondrey, currently serving as the Senior Vice President of Financial Planning and Analysis (FP&A) at Mirati Therapeutics, will take on the role of interim CFO. CFO Laurie Stelzer sold 4,647 shares of the businesss stock in a transaction on Friday, June 2nd.

Today's News

mirati therapeutics announces departure of cfo and interim replacement - best stocks. Aaron Ondrey, currently serving as the Senior Vice President of Financial Planning and Analysis (FP&A) at Mirati Therapeutics , will take on the role of interim CFO. Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June 15 at 8:40 am. Mirati Therapeutics has a consensus rating of “Hold” and an average target price of $59.08. CFO Laurie Stelzer sold 4,647 shares of the businesss stock in a transaction on Friday, June 2nd. Aaron Ondrey, senior vice president, financial planning and analysis (FP&A), Mirati. will assume the role of interim CFO and will be; Meherry promotes grounard Relationshipnda helm councillor Vertogyn Chief Financial Officer Laurie Stelzer will depart the company on September 8, 2023 to pursue an external opportunity.

Stock Profile

"Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California."

Keywords

The game is changing. There is a new strategy to evaluate Mirati Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Mirati Therapeutics are: Mirati, interim, Therapeutics, CFO, stock, Aaron, Ondrey, and the most common words in the summary are: therapeutic, mirati, august, inc, job, cancer, news, . One of the sentences in the summary was: CFO Laurie Stelzer sold 4,647 shares of the businesss stock in a transaction on Friday, June 2nd.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #mirati #august #inc #job #cancer #news.

Read more →

Youtube Subscribe

---